Lates News

Novo Nordisk (NVO.N) raised its earnings forecast for the second time this year due to an increased sales expectation for its obesity and diabetes drugs. Novo Nordisk stated that the adjusted operating profit for the second quarter of 2026 would be 33.389 billion Danish kroner, raising its outlook for the entire year. The largest expected decline in sales and profits this year is anticipated to be 6%, whereas the company had previously estimated that, at constant exchange rates, the decline could reach up to 12%. Novo Nordisk is competing with its rival Eli Lilly (LLY.N) in the obesity market. According to forecasts, this market is expected to grow to $120 billion annually by 2030.